Opinion
Volume 09:05, 2025

Journal of Formulation Science & Bioavailability

ISSN: 2577-0543

Open Access

Advancing Pulmonary Drug Delivery for Enhanced Bioavailability

Chen Wei*

Department of Pharmaceutical Engineering and Bioavailability, Tsinghua University, Beijing 100084, China.

Introduction

Pulmonary drug delivery systems are increasingly recognized for their potential to achieve systemic bioavailability, circumventing the limitations associated with conventional oral and parenteral administration routes. This approach harnesses the lungs' anatomical and physiological advantages, including their expansive surface area, a thin epithelial barrier, and extensive vascularization, to facilitate rapid drug absorption directly into the systemic circulation. Various strategies have been developed, such as nanoparticles, liposomes, and dry powder inhalers, which are meticulously designed to optimize drug loading capacity, particle size, and aerodynamic properties to ensure efficient deposition within the lungs and controlled drug release. Despite these advancements, challenges persist, including achieving uniform drug deposition across the lung, preventing enzymatic degradation of therapeutic agents, and mitigating potential inflammatory responses within the lung tissue. Nevertheless, ongoing research in material science and formulation engineering continues to pave the way for the development of effective and safe pulmonary therapeutics. [1]

Dry powder inhalers (DPIs) stand as a fundamental modality for pulmonary drug delivery aimed at achieving systemic absorption. The efficacy of DPIs is heavily reliant on sophisticated formulation design, which encompasses both carrier-based and carrier-free approaches, to attain optimal aerosol performance and predictable drug release kinetics. Significant progress has been made in particle engineering techniques, including spray drying and micronization, enabling the precise creation of respirable particles. Maintaining the stability of the drug formulation, both within the inhaler device and upon aerosolization, is paramount for ensuring consistent dosing and achieving desired therapeutic outcomes. A thorough understanding of powder characteristics and flowability is indispensable for developing robust DPIs capable of overcoming the physiological complexities of the respiratory tract. [2]

Lipid-based nanoparticles, encompassing structures like liposomes and solid lipid nanoparticles, present a promising avenue for the pulmonary delivery of a diverse array of therapeutics intended for systemic effects. Their inherent amphiphilic nature facilitates the encapsulation of both hydrophilic and lipophilic drug molecules, thereby protecting them from degradation within the lung environment and promoting cellular uptake. Surface modifications can be employed to enhance targeting capabilities and prolong the residence time of these nanoparticles in the lungs. While the biocompatibility and biodegradability of lipid-based systems are significant advantages, critical challenges related to formulation stability, scalability of production, and potential immunogenicity necessitate careful and thorough consideration during development. [3]

Polymeric nanoparticles offer a highly versatile platform for pulmonary drug delivery, owing to their tunable properties and their capacity to encapsulate a wide range of drug molecules. Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) and chitosan are frequently utilized in the fabrication of these nanoparticles. These nanoparticles can be strategically engineered to achieve controlled drug release profiles, enhance cellular uptake, and enable targeted delivery within the lung, ultimately contributing to improved systemic bioavailability. However, critical issues such as optimizing drug loading efficiency, preventing particle aggregation, and addressing potential toxicity concerns must be meticulously managed through rigorous formulation design and comprehensive characterization. [4]

Microneedles are emerging as a potential strategy for transpulmonary drug delivery, offering a minimally invasive method for achieving systemic absorption of therapeutic agents. Although primarily associated with transdermal delivery, the development of pulmonary microneedle arrays, specifically designed to penetrate the lung epithelium, holds the promise of enabling direct and rapid drug entry into the systemic circulation. This delivery route effectively bypasses first-pass metabolism in the liver and allows for precise dose control. Key considerations in the development of pulmonary microneedles include the selection of appropriate biocompatible materials, optimization of drug loading capacity, and the fine-tuning of mechanical properties necessary for safe and effective penetration of the delicate lung tissue. [5]

Aerosolized gene therapy for the treatment of systemic diseases through pulmonary delivery represents a rapidly evolving and promising field. Both viral and non-viral vectors are being extensively explored as means to deliver therapeutic genes to target cells within the body. The lungs, with their substantial surface area, provide an ideal environment for gene delivery, and the thin alveolar-capillary barrier facilitates the efficient entry of gene products into the systemic circulation. Significant challenges remain, including the achievement of efficient gene transfection, the prevention of adverse immune responses directed against the delivery vector, and the assurance of long-term gene expression. Nanocarriers play a crucial role in protecting the genetic material and enhancing its delivery to target sites. [6]

The development of advanced inhaler devices is paramount for optimizing the efficacy of pulmonary drug delivery systems intended for systemic effects. Innovations in nebulizers and metered-dose inhalers are primarily focused on improving the aerodynamic particle size distribution of the emitted aerosol, ensuring dose uniformity, and enhancing patient adherence to prescribed treatment regimens. The advent of smart inhalers, which incorporate sensors and connectivity features, allows for the monitoring of inhaler usage patterns and provides valuable feedback to patients, thereby improving therapeutic outcomes. The design of these sophisticated devices must carefully consider the intricate physiology of the respiratory

tract and the specific physicochemical properties of the drug formulation being delivered. [7]

Biocompatible and biodegradable hydrogels are currently being investigated as a novel approach for sustained pulmonary drug delivery for systemic applications. These innovative formulations can be instilled directly into the lungs or administered via nebulization, acting as a localized depot that facilitates controlled drug release over an extended period. The porous structure characteristic of hydrogels allows for efficient drug loading and subsequent diffusion, while their tunable swelling properties can be manipulated to precisely modulate drug release rates. Key challenges in this area include ensuring adequate aerosolization characteristics for nebulized hydrogels and maintaining their structural integrity within the dynamic lung environment. [8]

Mucoadhesive systems are recognized as a critical component for prolonging the residence time of drugs within the lungs, thereby increasing the opportunity for absorption and consequently improving systemic bioavailability. Polymers such as chitosan, carbopol, and hyaluronic acid are commonly employed in the development of mucoadhesive nanoparticles or microparticles. These systems are designed to adhere to the mucus layer that lines the respiratory epithelium, effectively preventing rapid clearance by the mucociliary escalator. A significant formulation challenge lies in optimizing the mucoadhesive properties of these systems while simultaneously ensuring satisfactory aerosol performance for efficient delivery. [9]

The pulmonary immune system presents a unique set of challenges and opportunities for drug delivery strategies. While it can contribute to the inflammatory response and the clearance of foreign particles, it also offers potential pathways for targeted delivery of therapeutic agents to immune cells residing within the lungs. Nanoparticles can be specifically engineered to interact with these pulmonary immune cells, thereby facilitating the targeted delivery of immunomodulatory agents or vaccines. A comprehensive understanding of the intricate interplay between nanomaterials and the lung immune microenvironment is essential for the successful design of safe and effective immunotherapeutics that are delivered via the pulmonary route. [10]

Description

Pulmonary drug delivery systems are gaining significant traction as an effective method for achieving systemic bioavailability, offering a viable alternative to traditional oral and parenteral routes. This approach leverages the lungs' unique physiological characteristics, including their vast surface area, thin epithelial barrier, and rich vascularization, to promote rapid drug absorption directly into the bloodstream. Strategies employed in this field involve the use of advanced delivery vehicles such as nanoparticles, liposomes, and dry powder inhalers, all meticulously engineered to optimize critical parameters like drug loading efficiency, particle size, and aerodynamic properties, ensuring efficient deposition in the lungs and controlled drug release. Despite these technological advancements, several challenges remain to be addressed, including achieving uniform drug distribution throughout the lung, preventing the enzymatic degradation of administered drugs, and managing potential inflammatory responses within the lung tissue. However, continuous research efforts in material science and formulation engineering are steadily advancing the development of safe and efficacious pulmonary therapeutics. [1]

Dry powder inhalers (DPIs) represent a cornerstone in the field of pulmonary drug delivery for systemic absorption. The success of DPIs is fundamentally linked to sophisticated formulation design, which explores both carrier-based and carrier-free strategies to achieve optimal aerosolization performance and predictable drug release kinetics. Significant progress in particle engineering techniques, such as spray drying and micronization, has enabled the creation of precisely sized respirable particles. The stability of the drug formulation, both within the inhaler device and upon aerosolization, is of paramount importance for ensuring consistent dosing and achieving therapeutic efficacy. A deep understanding of powder characteristics and flow properties is crucial for developing robust DPIs that can effectively overcome the physiological challenges presented by the respiratory tract. [2]

Lipid-based nanoparticles, including liposomes and solid lipid nanoparticles, are emerging as highly promising carriers for the pulmonary delivery of a broad spectrum of therapeutics aimed at systemic effects. Their inherent amphiphilic nature allows for the encapsulation of both hydrophilic and lipophilic drugs, offering protection from enzymatic degradation in the lungs and facilitating enhanced cellular uptake. Surface modifications can further improve targeting capabilities and extend the residence time of these nanocarriers within the lung. The inherent biocompatibility and biodegradability of lipid-based systems are significant advantages; however, critical challenges related to formulation stability, scalability of manufacturing, and potential immunogenicity require careful consideration during the development process. [3]

Polymeric nanoparticles provide a versatile and adaptable platform for pulmonary drug delivery, owing to their tunable properties and their capacity to encapsulate diverse drug molecules. Biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA) and chitosan, are frequently incorporated into these nanoparticle formulations. These nanoparticles can be engineered to achieve controlled drug release profiles, enhance cellular uptake mechanisms, and facilitate targeted delivery within the pulmonary system, ultimately contributing to improved systemic bioavailability. Nevertheless, critical issues such as optimizing drug loading efficiency, preventing particle aggregation, and mitigating potential toxicity necessitate meticulous formulation design and comprehensive characterization. [4]

Microneedles are gaining attention as a potential strategy for transpulmonary drug delivery, offering a minimally invasive approach for facilitating systemic drug absorption. While primarily developed for transdermal applications, pulmonary microneedle arrays, specifically designed to breach the lung epithelium, could enable direct and rapid entry of drugs into the systemic circulation. This delivery route effectively bypasses first-pass metabolism in the liver and allows for precise dose administration. Key considerations for the development of pulmonary microneedles include the selection of appropriate biocompatible materials, the optimization of drug loading capacity, and the fine-tuning of mechanical properties to ensure safe and effective penetration of the lung tissue. [5]

Aerosolized gene therapy for the treatment of systemic diseases via pulmonary delivery is a rapidly advancing field. Both viral and non-viral vectors are being actively investigated as vehicles to deliver therapeutic genes to target cells. The lungs, with their extensive surface area, provide a favorable environment for gene delivery, and the thin alveolar-capillary barrier facilitates the systemic circulation of gene products. Key challenges include achieving efficient gene transfection, preventing adverse immune responses against the vector, and ensuring sustained long-term gene expression. Nanocarriers are essential components for protecting the genetic material and enhancing its targeted delivery. [6]

The advancement of sophisticated inhaler devices is crucial for optimizing pulmonary drug delivery systems intended for systemic applications. Innovations in nebulizers and metered-dose inhalers are primarily focused on enhancing the aerodynamic particle size distribution of the generated aerosol, ensuring dose uniformity, and improving patient adherence to therapy. The emergence of smart inhalers, equipped with sensors and connectivity features, enables the monitoring of inhaler usage and provides feedback to patients, thereby improving therapeutic outcomes. The design of these devices must carefully account for the intricate physiology of the respiratory tract and the specific characteristics of the drug for-

mulation being delivered. [7]

Biocompatible and biodegradable hydrogels are being explored as a promising approach for sustained pulmonary drug delivery for systemic applications. These advanced formulations can be administered directly into the lungs or delivered via nebulization, serving as a localized depot for controlled drug release over extended periods. The porous architecture of hydrogels facilitates drug loading and diffusion, while their tunable swelling characteristics allow for precise modulation of release rates. Key challenges in this area include ensuring appropriate aerosolization properties for nebulized hydrogels and maintaining their structural integrity within the lung environment. [8]

Mucoadhesive systems play a vital role in extending the residence time of drugs within the lungs, thereby increasing the window for absorption and improving systemic bioavailability. Polymers such as chitosan, carbopol, and hyaluronic acid are commonly utilized in the development of mucoadhesive nanoparticles or microparticles. These systems are designed to adhere to the mucus layer coating the respiratory epithelium, which helps to prevent rapid clearance by the mucociliary escalator. A primary formulation challenge involves optimizing the mucoadhesive properties of these systems while simultaneously ensuring satisfactory aerosol performance for efficient lung deposition. [9]

The pulmonary immune system presents a complex interplay of challenges and opportunities for drug delivery. While it can trigger inflammatory responses and lead to the clearance of foreign particles, it also offers pathways for targeted delivery to resident immune cells within the lungs. Nanoparticles can be engineered to interact specifically with pulmonary immune cells, thereby facilitating the delivery of immunomodulatory agents or vaccines. A thorough understanding of the interactions between nanomaterials and the lung immune microenvironment is essential for the design of safe and effective immunotherapeutics delivered via the pulmonary route. [10]

Conclusion

Pulmonary drug delivery systems are rapidly advancing, offering systemic bioavailability by utilizing the lungs' large surface area and rich vascularization. These systems employ various strategies like nanoparticles, liposomes, and dry powder inhalers to enhance drug absorption, overcoming traditional route limitations. Key delivery vehicles include lipid-based nanoparticles, polymeric nanoparticles, and hydrogels, each designed with specific properties for controlled release and cellular uptake. Advanced inhaler devices and microneedles are also being developed to improve efficacy and patient adherence. While significant progress has been made, challenges such as uniform deposition, formulation stability, and immune responses persist. Research is ongoing to optimize these systems for effective and safe therapeutic outcomes, including targeted delivery to immune cells and gene therapy applications.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Saeed Khan, Saad Ullah Khan, Shahid Iqbal. "Pulmonary Nanomedicine for Systemic Drug Delivery: Current Status and Future Prospects." *Advanced Drug Delivery Reviews* 175 (2021):147-164.
2. Taha E. Abdel-Hameed, Yacoub M. Al-Shafiei, Hamada Abouseif. "Dry Powder Inhalers for Systemic Drug Delivery: Formulation Strategies and Challenges." *Pharmaceutics* 15 (2023):15(10):1234.
3. Ali R. Khadouri, Mohammad R. Jaafar, Iman S. Al-Khawaldeh. "Lipid-Based Nanoparticles for Pulmonary Drug Delivery: A Review." *International Journal of Pharmaceutics* 627 (2022):627:122246.
4. Chandan Kumar, Ashutosh S. Dhoble, Mohammad M. Hossain. "Polymeric Nanoparticles for Pulmonary Drug Delivery: Formulation, Characterization, and Therapeutic Applications." *Journal of Controlled Release* 328 (2020):328:293-308.
5. Yonggang Zhang, Bingjie Zhang, Wenjia Liu. "Pulmonary Microneedle Arrays for Systemic Drug Delivery: A Conceptual Review." *Expert Opinion on Drug Delivery* 20 (2023):20(1):1-12.
6. Svenja L. Hölzlwimmer, Johannes W. H. Eickhoff, Thomas H. M. Van Deursen. "Pulmonary Delivery of Gene Therapy for Systemic Diseases." *International Journal of Molecular Sciences* 22 (2021):22(15):7942.
7. Anuradha G. Deshpande, Ruiyi Li, Ying-Xiu Du. "Advanced Inhaler Devices for Pulmonary Drug Delivery: A Review." *Journal of Aerosol Medicine and Pulmonary Drug Delivery* 33 (2020):33(3):147-160.
8. Sonia Singh, Poonam Singh, Ritu Singh. "Hydrogels for Pulmonary Drug Delivery: Current Advances and Future Perspectives." *Biomacromolecules* 23 (2022):23(4):1501-1518.
9. Nafiseh Ghazi, Seyed A. Hoseini, Mostafa Lavasani. "Mucoadhesive Nanoparticles for Pulmonary Drug Delivery: A Review." *Journal of Drug Targeting* 31 (2023):31(3):231-246.
10. Samanthi A. Jayawardena, Thilina K. Jayasinghe, Niroshan S. Siriwardena. "Nanoparticle-Immune System Interactions in the Lungs: Implications for Pulmonary Drug Delivery." *Acta Biomaterialia* 132 (2021):132:154-167.

How to cite this article: Wei, Chen. "Advancing Pulmonary Drug Delivery for Enhanced Bioavailability." *J. Formul. Sci. Bioavailability* 09 (2025):257.

Address for Correspondence: Chen, Wei, Department of Pharmaceutical Engineering and Bioavailability, Tsinghua University, Beijing 100084, China., E-mail: chen.wei@tsinghua.edu.cn

Received: 02-Sep-2025, Manuscript No. fsb-26-189971; **Editor assigned:** 04-Sep-2025, PreQC No. P-189971; **Reviewed:** 18-Sep-2025, QC No. Q-189971; **Revised:** 23-Sep-2025, Manuscript No. R-189971; **Published:** 30-Sep-2025, DOI: 10.37421/2577-0543.2025.9.257